The global preclinical CRO market size was exhibited at USD 5.33 billion in 2022 and is projected to hit around USD 10.60 billion by 2032, growing at a CAGR of 7.11% during the forecast period 2023 to 2032.
The global preclinical CRO market size was exhibited at USD 5.33 billion in 2022 and is projected to hit around USD 10.60 billion by 2032, growing at a CAGR of 7.11% during the forecast period 2023 to 2032.
Download Free Sample Copy for Better Understanding@
https://www.novaoneadvisor.com/report/sample/6146
Key Takeaway:
- North America accounts for the largest share of 48.64% in 2022
- Asia Pacific is also anticipated to grow with the fastest rate of 10.11% during the forecast period.
- The toxicology testing segment accounted for the largest revenue share of 26.48% of the global preclinical CRO market in 2022
- The bioanalysis and DMPK studies segment is expected to register the fastest CAGR of 8.6% during the forecast period.
- The Patient Derived Organoid (PDO) Model segment held the largest share of 81.47% in 2022.
- The biopharmaceutical companies segment is expected to hold the largest market share of 81.49% in 2022.
- The government and academic institutes segment is estimated to register the fastest growth of 8.3% during the forecast period.
Procure Complete Report (250 Pages PDF with Insights, Charts, Tables, and Figures)@ https://www.novaoneadvisor.com/report/checkout/6146
The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period. However, the COVID-19 pandemic had temporarily affected the market owing to the shutdown of research sites due to the implementation of national lockdowns.
The market is undergoing a series of mergers and acquisitions, resulting in improvement in full-service capabilities and the international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.
The COVID-19 pandemic is ever increasing since the disease was first identified in China in December 2019. Until March 9, 2022, more than 4500 million cases of COVID-19 were reported globally; this pandemic has fast-tracked the development of vaccines and drug testing. There are currently over 195 COVID-19 vaccine candidates in preclinical studies.
Service Insights
The toxicology testing segment accounted for the largest revenue share of 26.48% of the global preclinical CRO market in 2022, owing to a rise in outsourcing of noncore preclinical CRO studies and high adoption of toxicology tests. Toxicology is one of the key services, which is being outsourced to CROs owing to the improved capabilities of CROs to conduct toxicology tests. The growing rate of outsourcing noncore preclinical studies to the CROs and the growing capabilities of CROs to offer additional value-added services is expected to propel the growth of this segment during the forecast period.
The bioanalysis and DMPK studies segment is expected to register the fastest CAGR of 8.6% during the forecast period. The segment is expected to witness lucrative growth on account of a rise in the demand for pharmacokinetic services to support toxicology tests for IND-enabling studies. In addition, bioanalysis and DMPK studies are vital in the entire drug development process. They are performed in every stage of the drug development process and are not confined to the preclinical phase. These factors are further contributing to the segment growth.
Model Type Insights
The Patient Derived Organoid (PDO) Model segment held the largest share of 81.47% in 2022. The growing impact of the patient-derived organoid (PDO) model is due to the use of direct derived cells and tissues from the patient. This helps in personalized healthcare and the specimens can be cryopreserved. For these reasons, they are becoming an essential part of preclinical studies as they help in quicker diagnosis and prognosis of malignancy.
The Patient derived xenograft model market has been analyzed to grow steadily during the forecast period. This is attributed to the growing number of CROs maintaining an in-house inventory of immunodeficient mice with patient-derived xenografts (PDXs). Furthermore, this type of analysis allows for researchers to co-relate the laboratory research with humans, owing to the maintenance of the original genetic makeup of the tumor cells. Also, the responses observed in clinical trials among patients have been found to correlate with the responses in these patient-derived xenografts, which in turn allows for a better safety profile and thus expedites the approval of New Drug Investigation (NDA).
End-use Insights
The biopharmaceutical companies segment is expected to hold the largest market share of 81.49% in 2022. The increasing trend of outsourcing end-to-end services among biopharmaceutical companies, especially amongst the small- and mid-size companies that lack sufficient expertise in the preclinical phase of drug development, is expected to boost the demand for preclinical CRO services in the future.
The government and academic institutes segment is estimated to register the fastest growth of 8.3% during the forecast period. Academia and government bodies play a crucial role in the preclinical phase of discovery and development. In addition, an increasing number of academic organizations and government bodies outsourcing preclinical services to CROs will boost the segment growth. Academic institutes are one of the major sources of revenue for big CROs, such as Charles River Laboratories and LabCorp.
Regional Insights
North America accounts for the largest share of 48.64% in 2022 owing to the presence of established CROs specializing in early drug discovery, such as Charles River Laboratories and LabCorp. The U.S. is the biggest market for preclinical trial outsourcing, as several biopharmaceutical companies prefer outsourcing their preclinical trials to CROs based in the U.S., to seek benefit from the Investigational New Drug (IND) application, approved by the FDA.
Asia Pacific is also anticipated to grow with the fastest rate of 10.11% during the forecast period. The changing business model of MNC outsourcing and the rising cost of R&D is expected to increase preclinical outsourcing in the Asia Pacific, owing to the cost efficiency offered by CROs in countries such as India and China. Established companies located in Western Europe and the U.S. pursue analytical services, site research development, and clinical activities in the Asia Pacific region in order to reduce the cost associated with research.
Some of the prominent players in the Preclinical CRO Market include:
- Eurofins Scientific
- PRA Health Sciences, Inc.
- Wuxi AppTec
- Medpace, Inc.
- Charles River Laboratories International, Inc.
- Pharmaceutical Product Development (PPD), LLC
- SGS SA (SGS)
- Intertek Group Plc (IGP)
- Laboratory Corporation of America, Inc.
- Crown Bioscience
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Preclinical CRO market.
By Service
- Bioanalysis and DMPK studies
- In vitro ADME
- In-vivo PK
- Toxicology Testing
- GLP
- Non-GLP
- Compound Management
- Process R&D
- Custom Synthesis
- Others
- Chemistry
- Medicinal Chemistry
- Computation Chemistry
- Safety Pharmacology
- Others
By Model Type
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
By End-use
- Biopharmaceutical Companies
- Government and Academic Institutes
- Medical Device Companies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/6146
Unlocking Market Insights through Data Excellence
The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.
Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
About US
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
Connect with US
- Apt 1408 1785 RiversideDrive Ottawa, ON, K1G 3T7, Canada
- 2nd Floor, Shreeleela Plaza, Baner Road,Pune, Maharashtra - 411045
- USA - +1 9197 992 333 IND - +91 93077 85324
- sales@novaoneadvisor.com
Web: https://www.novaoneadvisor.com/
Blog: https://www.precedenceresearch.com/
Blog: https://www.visionresearchreports.com/